methyldopa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
dopamine receptor agonists, dopamine derivatives, used as antiparkinsonism/prolactin inhibitors 1762 555-30-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methyldopa (levorotatory)
  • methyldopa
  • aldochlor
  • aldomine
  • alphamethyldopa
  • lederdopa
  • (-)-alpha-Methyl-3,4-dihydroxyphenylalanine
An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.
  • Molecular weight: 211.22
  • Formula: C10H13NO4
  • CLOGP: -2.26
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 103.78
  • ALOGS: -1.97
  • ROTB: 3
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g O
1 g P
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 40 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 157.66 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 42 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.69 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.85 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 20, 1962 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Premature delivery 1506.60 24.50 415 8360 29866 63450381
Exposure during pregnancy 1211.69 24.50 532 8243 155015 63325232
Maternal exposure during pregnancy 1126.99 24.50 563 8212 219499 63260748
Foetal exposure during pregnancy 726.42 24.50 240 8535 31722 63448525
Premature baby 671.30 24.50 204 8571 20531 63459716
Pre-eclampsia 446.96 24.50 124 8651 9009 63471238
Low birth weight baby 349.69 24.50 97 8678 7032 63473215
Live birth 279.03 24.50 112 8663 25518 63454729
Caesarean section 270.30 24.50 98 8677 16934 63463313
Foetal growth restriction 264.18 24.50 79 8696 7474 63472773
Oligohydramnios 259.61 24.50 75 8700 6291 63473956
Patent ductus arteriosus 237.04 24.50 64 8711 4186 63476061
Premature labour 221.21 24.50 78 8697 12426 63467821
Atrial septal defect 176.98 24.50 57 8718 6881 63473366
HELLP syndrome 141.06 24.50 32 8743 1012 63479235
Normal newborn 139.78 24.50 50 8725 8291 63471956
Small for dates baby 117.25 24.50 36 8739 3715 63476532
Gestational diabetes 113.59 24.50 43 8732 8353 63471894
Ventricular septal defect 111.77 24.50 36 8739 4342 63475905
Placental insufficiency 105.80 24.50 27 8748 1414 63478833
Polyhydramnios 102.62 24.50 29 8746 2242 63478005
Hypotonia neonatal 94.69 24.50 24 8751 1222 63479025
Conjoined twins 92.62 24.50 18 8757 262 63479985
Neonatal respiratory distress syndrome 92.14 24.50 28 8747 2790 63477457
Neonatal respiratory failure 91.80 24.50 18 8757 275 63479972
Intestinal malrotation 87.14 24.50 18 8757 362 63479885
Selective eating disorder 82.60 24.50 24 8751 2048 63478199
Proteinuria 82.43 24.50 44 8731 19101 63461146
Neonatal seizure 81.44 24.50 18 8757 504 63479743
Foetal death 79.58 24.50 36 8739 10944 63469303
Premature rupture of membranes 72.73 24.50 27 8748 4966 63475281
Congenital bladder anomaly 68.11 24.50 13 8762 171 63480076
Urachal abnormality 67.56 24.50 13 8762 179 63480068
Ureteric stenosis 67.49 24.50 16 8759 615 63479632
Persistent cloaca 66.71 24.50 13 8762 192 63480055
Congenital choroid plexus cyst 66.44 24.50 14 8761 311 63479936
Gestational hypertension 66.32 24.50 21 8754 2396 63477851
Respiratory disorder neonatal 61.27 24.50 17 8758 1228 63479019
Microcephaly 61.16 24.50 16 8759 924 63479323
Hypoglycaemia neonatal 60.58 24.50 16 8759 959 63479288
Ultrasound uterus abnormal 58.87 24.50 10 8765 64 63480183
Retrognathia 56.41 24.50 13 8762 441 63479806
Premature separation of placenta 54.52 24.50 17 8758 1844 63478403
Newborn persistent pulmonary hypertension 53.12 24.50 11 8764 224 63480023
Ovarian cyst 50.58 24.50 30 8745 15915 63464332
Neonatal asphyxia 49.83 24.50 11 8764 306 63479941
Exposure via breast milk 48.78 24.50 16 8759 2041 63478206
Stillbirth 48.49 24.50 22 8753 6728 63473519
Pregnancy 47.62 24.50 40 8735 36796 63443451
Drug-induced liver injury 46.55 24.50 41 8734 40181 63440066
Toxoplasmosis 44.98 24.50 14 8761 1509 63478738
Phaeochromocytoma 44.44 24.50 11 8764 508 63479739
Fatigue 43.02 24.50 36 8739 887992 62592255
Foetal distress syndrome 42.48 24.50 13 8762 1325 63478922
Adiposis dolorosa 39.09 24.50 9 8766 304 63479943
Rash 38.11 24.50 15 8760 560856 62919391
Congenital hydronephrosis 36.41 24.50 9 8766 413 63479834
Hypertonia neonatal 35.79 24.50 8 8767 236 63480011
Dysmorphism 35.59 24.50 13 8762 2283 63477964
Breech presentation 35.19 24.50 11 8764 1203 63479044
Foetal exposure timing unspecified 34.98 24.50 8 8767 262 63479985
Cerebellar hypoplasia 34.83 24.50 7 8768 122 63480125
Diarrhoea 34.58 24.50 29 8746 715337 62764910
Renal hypertension 33.37 24.50 7 8768 152 63480095
Diaphragmatic paralysis 32.92 24.50 9 8766 615 63479632
Blood pressure diastolic increased 32.18 24.50 19 8756 9991 63470256
Blood pressure inadequately controlled 31.93 24.50 15 8760 4963 63475284
Maternal condition affecting foetus 31.50 24.50 7 8768 201 63480046
Delayed fontanelle closure 31.39 24.50 5 8770 20 63480227
Pneumonia 31.36 24.50 12 8763 456755 63023492
Foetal heart rate deceleration abnormality 29.94 24.50 8 8767 501 63479746
Congenital cerebral cyst 29.65 24.50 7 8768 264 63479983
Preterm premature rupture of membranes 29.59 24.50 10 8765 1399 63478848
Bicuspid aortic valve 29.32 24.50 6 8769 115 63480132
Abortion spontaneous 28.70 24.50 34 8741 47161 63433086
Abdominal discomfort 28.53 24.50 5 8770 320880 63159367
Cervical incompetence 28.42 24.50 8 8767 609 63479638
Neonatal hypoxia 28.19 24.50 8 8767 627 63479620
Maternal exposure during breast feeding 27.88 24.50 13 8762 4228 63476019
Peripartum cardiomyopathy 27.83 24.50 6 8769 149 63480098
Death 27.11 24.50 9 8766 374372 63105875
Renal failure neonatal 26.65 24.50 6 8769 183 63480064
Congenital aortic valve stenosis 26.04 24.50 5 8770 68 63480179
Oliguria 25.96 24.50 16 8759 9085 63471162
Fall 25.79 24.50 11 8764 392323 63087924
Blood pressure diastolic abnormal 25.71 24.50 19 8756 14523 63465724
Bradyarrhythmia 25.62 24.50 10 8765 2105 63478142
Blood albumin decreased 25.45 24.50 19 8756 14747 63465500
Maternal drugs affecting foetus 25.27 24.50 13 8762 5229 63475018
Arthralgia 25.23 24.50 25 8750 569685 62910562
Hypersensitivity 25.07 24.50 5 8770 292680 63187567
Bradycardia neonatal 25.00 24.50 8 8767 944 63479303
Drug intolerance 24.97 24.50 6 8769 308655 63171592
Posterior reversible encephalopathy syndrome 24.84 24.50 20 8755 17325 63462922
Cleft palate 24.52 24.50 8 8767 1004 63479243

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Foetal exposure during pregnancy 1055.99 44.74 305 3113 37796 34915717
Premature baby 904.81 44.74 235 3183 19398 34934115
Low birth weight baby 581.07 44.74 138 3280 7767 34945746
Atrial septal defect 400.13 44.74 101 3317 7291 34946222
Small for dates baby 290.28 44.74 69 3349 3858 34949655
Foetal growth restriction 241.18 44.74 60 3358 4057 34949456
Patent ductus arteriosus 212.16 44.74 52 3366 3302 34950211
Respiratory disorder neonatal 181.41 44.74 40 3378 1590 34951923
Hypospadias 169.26 44.74 43 3375 3158 34950355
Large for dates baby 162.18 44.74 33 3385 885 34952628
Infantile apnoea 154.82 44.74 32 3386 929 34952584
Hypoglycaemia neonatal 148.70 44.74 35 3383 1866 34951647
Selective eating disorder 140.45 44.74 33 3385 1745 34951768
Diabetic foetopathy 137.62 44.74 23 3395 196 34953317
Foetal disorder 112.83 44.74 24 3394 802 34952711
Ventricular septal defect 109.47 44.74 32 3386 3969 34949544
Neonatal respiratory distress syndrome 100.47 44.74 30 3388 4004 34949509
Neonatal respiratory failure 100.20 44.74 19 3399 349 34953164
Maternal exposure during pregnancy 98.77 44.74 31 3387 4887 34948626
Bradycardia neonatal 92.43 44.74 21 3397 955 34952558
Caesarean section 89.84 44.74 24 3394 2140 34951373
Maternal drugs affecting foetus 88.06 44.74 27 3391 3938 34949575
Congenital hydronephrosis 87.15 44.74 19 3399 714 34952799
Pulmonary hypoplasia 82.67 44.74 17 3401 480 34953033
Neutropenia neonatal 76.58 44.74 17 3401 695 34952818
Cryptorchism 63.28 44.74 18 3400 2023 34951490
Exposure during pregnancy 63.19 44.74 26 3392 8908 34944605
Hydrops foetalis 62.76 44.74 15 3403 852 34952661
Pulmonary valve stenosis congenital 62.46 44.74 11 3407 131 34953382
Hypotonia neonatal 60.99 44.74 16 3402 1329 34952184
Congenital cystic lung 50.84 44.74 10 3408 224 34953289
Acoustic stimulation tests abnormal 47.66 44.74 8 3410 70 34953443
Apgar score low 47.16 44.74 12 3406 883 34952630
Eyelid ptosis congenital 45.92 44.74 8 3410 89 34953424
Supernumerary nipple 44.93 44.74 7 3411 36 34953477
Agitation neonatal 44.75 44.74 12 3406 1084 34952429

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Premature delivery 1290.66 22.90 322 7200 23145 79713721
Exposure during pregnancy 1287.39 22.90 445 7077 100687 79636179
Maternal exposure during pregnancy 1218.53 22.90 462 7060 136076 79600790
Pre-eclampsia 479.27 22.90 115 7407 6926 79729940
Live birth 338.65 22.90 108 7414 18636 79718230
Oligohydramnios 238.61 22.90 57 7465 3355 79733511
Caesarean section 237.79 22.90 75 7447 12460 79724406
Premature labour 213.81 22.90 63 7459 8327 79728539
Premature baby 207.63 22.90 52 7470 3728 79733138
Foetal growth restriction 188.29 22.90 43 7479 2076 79734790
Normal newborn 153.80 22.90 47 7475 7025 79729841
HELLP syndrome 131.68 22.90 27 7495 779 79736087
Gestational diabetes 129.11 22.90 40 7482 6253 79730613
Placental insufficiency 117.23 22.90 26 7496 1097 79735769
Foetal exposure during pregnancy 107.08 22.90 34 7488 5756 79731110
Polyhydramnios 106.20 22.90 26 7496 1694 79735172
Foetal death 81.13 22.90 30 7492 8014 79728852
Premature rupture of membranes 79.84 22.90 25 7497 4044 79732822
Proteinuria 76.39 22.90 44 7478 32458 79704408
Gestational hypertension 70.02 22.90 19 7503 1860 79735006
Stillbirth 68.10 22.90 22 7500 3933 79732933
Oesophageal atresia 59.00 22.90 10 7512 97 79736769
Teratogenicity 50.49 22.90 10 7512 241 79736625
Ultrasound uterus abnormal 47.25 22.90 7 7515 25 79736841
Drug-induced liver injury 46.35 22.90 43 7479 66074 79670792
Phaeochromocytoma 45.87 22.90 11 7511 656 79736210
Abortion spontaneous 44.16 22.90 30 7492 29477 79707389
Adiposis dolorosa 42.51 22.90 9 7513 304 79736562
Toxoplasmosis 42.38 22.90 14 7508 2683 79734183
Premature separation of placenta 39.05 22.90 11 7511 1235 79735631
Hypertension 38.89 22.90 92 7430 330900 79405966
Ovarian cyst 37.59 22.90 20 7502 12635 79724231
Pregnancy 37.12 22.90 26 7496 26825 79710041
Low birth weight baby 36.35 22.90 9 7513 614 79736252
Maternal condition affecting foetus 35.65 22.90 7 7515 161 79736705
Blood pressure inadequately controlled 34.32 22.90 15 7507 6162 79730704
Umbilical cord vascular disorder 33.72 22.90 5 7517 18 79736848
Blood pressure diastolic increased 32.33 22.90 19 7503 14523 79722343
Vaginal haemorrhage 32.21 22.90 22 7500 21795 79715071
Diaphragmatic paralysis 31.18 22.90 9 7513 1103 79735763
Posterior reversible encephalopathy syndrome 30.74 22.90 23 7499 26258 79710608
Peripartum cardiomyopathy 30.36 22.90 6 7516 143 79736723
Salivary gland cancer stage IV 28.02 22.90 5 7517 67 79736799
Cervical incompetence 27.69 22.90 7 7515 520 79736346
Blood pressure diastolic abnormal 27.49 22.90 19 7503 19183 79717683
Maternal exposure during breast feeding 26.66 22.90 10 7512 2775 79734091
Ventricular hypertrophy 26.52 22.90 13 7509 6925 79729941
Preterm premature rupture of membranes 25.72 22.90 8 7514 1265 79735601
Oliguria 25.40 22.90 17 7505 16292 79720574
Blood pressure increased 25.05 22.90 59 7463 211301 79525565
Diabetic foetopathy 24.89 22.90 4 7518 27 79736839
Postpartum haemorrhage 23.94 22.90 8 7514 1587 79735279
Blood albumin decreased 23.53 22.90 19 7503 24224 79712642
Abortion induced 23.29 22.90 12 7510 7097 79729769

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neonatal respiratory failure 38.07 26.60 33 1359 252 88148

Pharmacologic Action:

SourceCodeDescription
ATC C02AB01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Methyldopa
ATC C02AB02 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Methyldopa
ATC C02LB01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
Methyldopa and diuretics in combination
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013565 Sympatholytics
CHEBI has role CHEBI:35569 alpha-adrenergic agonists
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:49110 peripheral nervous system drugs
CHEBI has role CHEBI:59174 haptens
CHEBI has role CHEBI:66991 sympatholytic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Cirrhosis of liver contraindication 19943007 DOID:5082
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Parkinsonism contraindication 32798002
Dehydration contraindication 34095006
Depressive disorder contraindication 35489007
Hyperuricemia contraindication 35885006 DOID:1920
Acute hepatitis contraindication 37871000
Hypokalemia contraindication 43339004
Chronic heart failure contraindication 48447003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Oliguria contraindication 83128009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Hypomagnesemia contraindication 190855004
Angina pectoris contraindication 194828000
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Neonatal hyperbilirubinemia contraindication 281610001
Pheochromocytoma contraindication 302835009
Hypertriglyceridemia contraindication 302870006
Autoimmune hemolytic anemia contraindication 413603009 DOID:718
Porphyria contraindication 418470004
Azotemia contraindication 445009001
Severe Cerebrovascular Disease contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.51 acidic
pKa2 8.98 acidic
pKa3 13.39 acidic
pKa4 10.04 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-2A adrenergic receptor GPCR AGONIST WOMBAT-PK CHEMBL
Aromatic-L-amino-acid decarboxylase Enzyme WOMBAT-PK
Epidermal growth factor receptor Kinase IC50 5.28 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.29 DRUG MATRIX
Lysine-specific demethylase 4E Enzyme IC50 5.52 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.67 DRUG MATRIX

External reference:

IDSource
4017896 VUID
N0000146248 NUI
D08205 KEGG_DRUG
4017896 VANDF
C0025741 UMLSCUI
CHEBI:61058 CHEBI
CHEMBL459 ChEMBL_ID
CHEMBL718 ChEMBL_ID
DB00968 DRUGBANK_ID
D008750 MESH_DESCRIPTOR_UI
38853 PUBCHEM_CID
56LH93261Y UNII
6876 RXNORM
1035 MMSL
5088 MMSL
d00133 MMSL
000646 NDDF
373542000 SNOMEDCT_US
84078002 SNOMEDCT_US
41372-08-1 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 16729-029 TABLET, FILM COATED 125 mg ORAL ANDA 23 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 16729-030 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 16729-031 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 21695-879 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 21695-880 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 42254-351 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 54868-0050 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 54868-1328 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 62135-321 TABLET, FILM COATED 250 mg ORAL NDA 11 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 62135-322 TABLET, FILM COATED 500 mg ORAL NDA 11 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 68151-2791 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections